CERT

Certara Inc

Add to Watchlist

Advanced Chart

10.500

-0.16(-1.501%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.840

Open

10.690

VWAP

10.54

Vol

1.20M

Mkt Cap

1.69B

Low

10.390

Amount

12.62M

EV/EBITDA(TTM)

17.92

Total Shares

160.84M

1.84B

EV/OCF(TTM)

18.16

P/S(TTM)

4.23

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

113.39M

+6.97%

0.139

-0.81%

107.00M

+6.61%

0.115

-23.46%

104.66M

+10.37%

0.110

-15.1%

Estimates Revision

The market is revising No Change the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.38%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-8.38%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 14.17 USD with a low forecast of 11.50 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 10.500

Low

11.50

Averages

14.17

High

16.00

Current: 10.500

Low

11.50

Averages

14.17

High

16.00

Morgan Stanley

Equal Weight

initiated

$16

2025-07-03

Reason

Morgan Stanley

Price Target

$16

2025-07-03

initiated

Equal Weight

Reason

Morgan Stanley assumed coverage of Certara with an Equal Weight rating and $16 price target. The firm says it awaits further potential updates on Certara's strategic review of the regulatory services business and management commentary regarding the near- or mid-term impact that may result from Certara's opportunity set coming from the FDA's previous announcement to gradually reduce animal testing in favor of new approach methodologies.

Barclays

Luke Sergott

Equal Weight -> Overweight

upgrade

$11 -> $14

2025-05-08

Reason

Barclays

Luke Sergott

Price Target

$11 -> $14

2025-05-08

upgrade

Equal Weight -> Overweight

Reason

Barclays analyst Luke Sergott upgraded Certara to Overweight from Equal Weight with a price target of $14, up from $11. The firm believes the company is more favorably positioned with potential macro and policy headwinds versus the majority of its peers sector. Shares at current levels offer an attractive entry point, the analyst tells investors in a research note. While it is still early days, Certara's simulation modeling functions more in the earlier stages of drug discovery, and the business is well positioned to capture Tailwinds from the transition away from animal models, contends Barclays.

Keybanc

Scott Schoenhaus

Buy

Maintains

$15 → $18

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$15 → $18

2025-04-16

Maintains

Buy

Reason

KeyBanc raised the firm's price target on Certara to $18 from $15 and keeps an Overweight rating on the shares. . Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Baird

Joe Vruwink

Hold

Maintains

$9 → $13

2025-04-11

Reason

Baird

Joe Vruwink

Price Target

$9 → $13

2025-04-11

Maintains

Hold

Reason

Baird analyst Joe Vruwink raised the firm's price target on Certara to $13 from $9 and keeps a Neutral rating on the shares. The firm updated its model after the FDA offered a strong endorsement for Biosimulation.

Barclays

Luke Sergott

Hold

Maintains

$13 → $11

2025-04-10

Reason

Barclays

Luke Sergott

Price Target

$13 → $11

2025-04-10

Maintains

Hold

Reason

Barclays lowered the firm's price target on Certara to $11 from $13 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.

Barclays

Luke Sergott

Hold

Maintains

$12 → $13

2025-02-28

Reason

Barclays

Luke Sergott

Price Target

$12 → $13

2025-02-28

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Certara Inc (CERT.O) is 21.47, compared to its 5-year average forward P/E of 51.24. For a more detailed relative valuation and DCF analysis to assess Certara Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

51.24

Current PE

21.47

Overvalued PE

87.29

Undervalued PE

15.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

26.26

Current EV/EBITDA

13.79

Overvalued EV/EBITDA

37.98

Undervalued EV/EBITDA

14.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

8.93

Current PS

3.98

Overvalued PS

13.31

Undervalued PS

4.54